Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDP-001
- Development stage
- Phase 2
- Lead developer
- InduPro
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IDP-001 is a first-in-class bispecific antibody-drug conjugate (ADC) being developed by InduPro Soluciones for the treatment of solid tumors. Utilizing the company's proprietary MInt (Membrane Interactomics) platform, IDP-001 was designed to target the epidermal growth factor receptor (EGFR) and CUB domain-containing protein 1 (CDCP1), also known as tumor-associated proximity antigen E1 (TAPA-E1). The drug consists of a bispecific antibody conjugated to the microtubule inhibitor monomethyl auristatin E (MMAE) with a drug-to-antibody ratio (DAR) of 2. This proximity-based approach requires the co-localization of both targets on the cell surface for optimal engagement, thereby enhancing therapeutic index by sparing normal tissues that may express only one of the targets. IDP-001 is currently in IND-enabling preclinical development.
- Other names
- EGFR x TAPA-E1 bispecific ADCEGFR x CDCP1 bispecific ADC
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)CDCP1 (CUB domain-containing protein 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on IDP-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDP-001.